RU2094059C1 - Method of transport of neurotropic preparation to brain - Google Patents

Method of transport of neurotropic preparation to brain Download PDF

Info

Publication number
RU2094059C1
RU2094059C1 RU93043262A RU93043262A RU2094059C1 RU 2094059 C1 RU2094059 C1 RU 2094059C1 RU 93043262 A RU93043262 A RU 93043262A RU 93043262 A RU93043262 A RU 93043262A RU 2094059 C1 RU2094059 C1 RU 2094059C1
Authority
RU
Russia
Prior art keywords
neurotropic
brain
transport
preparation
drug
Prior art date
Application number
RU93043262A
Other languages
Russian (ru)
Other versions
RU93043262A (en
Inventor
Р.Н. Аляутдин
В.Е. Петров
С.В. Елецкая
И.Н. Топчиева
Original Assignee
Московский государственный университет, химический факультет
Московское научно-производственное объединение "НИОПИК"
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Московский государственный университет, химический факультет, Московское научно-производственное объединение "НИОПИК" filed Critical Московский государственный университет, химический факультет
Priority to RU93043262A priority Critical patent/RU2094059C1/en
Publication of RU93043262A publication Critical patent/RU93043262A/en
Application granted granted Critical
Publication of RU2094059C1 publication Critical patent/RU2094059C1/en

Links

Images

Abstract

FIELD: medicine, biological chemistry. SUBSTANCE: method involves preparing the preparation solution in transport agent that is a conjugate of cyclodextrin with polyethylene oxide at the preparation concentration 0.01-0.1 g/ml. Method ensures to increase latent yield of corazol-induced convulsions and prevents their in some cases. EFFECT: improved method of transport. 1 tbl

Description

Изобретение относится к области биологии, а именно к способам транспорта нейротропных препаратов, например, [CH3CONH(CH2)3SO3]2Ca АОТА, в мозг.The invention relates to the field of biology, and in particular to methods of transporting neurotropic drugs, for example, [CH 3 CONH (CH 2 ) 3 SO 3 ] 2 Ca AOTA, to the brain.

Известный способ транспорта АОТА в мозг заключается во введении препарата в физиологическом растворе в кровоток [1]
Однако этот способ обладает низкой эффективностью, так как не обеспечивает подавления действия агентов, вызывающих судороги, а лишь увеличивает латентный период до наступления судорог.
A known method of transporting AOTA to the brain is the introduction of the drug in physiological saline into the bloodstream [1]
However, this method has low efficiency, since it does not suppress the action of agents that cause seizures, but only increases the latent period before the onset of seizures.

Задача изобретения изыскание такого способа транспорта нейротропных препаратов в мозг, который бы позволил не только увеличить латентный период до наступления судорог, но и предотвратить их наступление. Для решения этой задачи предложен способ транспорта нейротропных препаратов в мозг, заключающийся в том, что в качестве транспортного средства используют конъюгаты циклодекстринов с полиэтиленоксидом общей формулы

Figure 00000001

где n 6 12;
m 6-7.The objective of the invention is the search for such a method of transporting neurotropic drugs to the brain, which would not only increase the latent period before the onset of seizures, but also prevent their onset. To solve this problem, a method for the transport of neurotropic drugs to the brain is proposed, which consists in the use of conjugates of cyclodextrins with polyethylene oxide of the general formula
Figure 00000001

where n 6 12;
m 6-7.

Водный раствор конъюгата и нейротропного препарата с концентрацией препарата 0,01-0,1 г/мл вводят в кровоток. An aqueous solution of the conjugate and neurotropic drug with a concentration of the drug of 0.01-0.1 g / ml is injected into the bloodstream.

Концентрация препарата менее 0,01 г/мл не дает эффекта, а при концентрации более 0,1 г/мл увеличивается токсичность. Эффективность описанных конъюгатов в качестве транспортного средства не могла быть предсказана заранее, так как они обладают сложной пространственной структурой. Скорее всего их успешное применение связано с сочетанием в них способности солюбилизации и мембранотропных свойств, что и обеспечило перенос нейротропных препаратов через биологические мембраны. The concentration of the drug less than 0.01 g / ml does not give an effect, and at a concentration of more than 0.1 g / ml toxicity increases. The effectiveness of the described conjugates as a vehicle could not be predicted in advance, since they have a complex spatial structure. Most likely, their successful use is associated with a combination of the solubilization ability and membrane-active properties in them, which ensured the transfer of neurotropic drugs through biological membranes.

Эффективность предложенного способа проверялась в опытах in vivo на белых мышах. В качестве препарата, вызывающего судороги, применялся коразол. Регистрировалась продолжительность латентного периода до наступления судорог. При статистической обработке результатов использовали критерий Стьюденста. The effectiveness of the proposed method was tested in in vivo experiments on white mice. As a drug that causes seizures, corazole was used. The duration of the latent period before the onset of seizures was recorded. For statistical processing of the results, the Student test was used.

Пример 1. Готовят раствор, содержащий 0,18 г конъюгата β-циклодекстрина с полиэтиленоксидом (n 12, мол. масса 4900) и 0,015 г АОТА в 1 мл воды. Этот раствор в количестве 0,2 мл вводят внутривенно группе из шести белых мышей самцов линии L весом 18-20 г. Через 1 ч после введения препарата внутрибрюшинно вводят препарат, вызывающий судороги коразол (0,3 мл 1%-ного раствора) и регистрируют латентный период до наступления судорог. Example 1. A solution is prepared containing 0.18 g of a conjugate of β-cyclodextrin with polyethylene oxide (n 12, mol. Mass 4900) and 0.015 g of AOTA in 1 ml of water. This solution in an amount of 0.2 ml is administered intravenously to a group of six white mice of male L-line weighing 18-20 g. 1 h after administration of the drug, a drug causing convulsions of corazole is injected intraperitoneally (0.3 ml of a 1% solution) and recorded latent period before convulsions.

Результат испытаний приведен в таблице. The test result is shown in the table.

Пример 2. Готовят раствор, содержащий 0,56 г конъюгата, описанного в примере 1, и 0,030 АОТА в 1 мл. Далее испытание проводят по методике примера 1. Example 2. A solution is prepared containing 0.56 g of the conjugate described in Example 1 and 0.030 AOTA in 1 ml. Next, the test is carried out according to the method of example 1.

Результат испытаний приведен в таблице. The test result is shown in the table.

Пример 3. Испытания проводят по методике примера 1, но используют конъюгат b-циклодекстрина с полиэтиленоксидом с молекулярной массой 3000 и n 6. Example 3. The tests are carried out according to the method of example 1, but using a conjugate of b-cyclodextrin with polyethylene oxide with a molecular weight of 3000 and n 6.

Результат испытаний приведен в таблице. The test result is shown in the table.

Пример 4. Испытания проводят по методике примера 1, но берут конъюгат b-циклодекстрина с полиэтиленоксидом с молекулярной массой 4200 и п 10. Example 4. The tests are carried out according to the method of example 1, but take the conjugate of b-cyclodextrin with polyethylene oxide with a molecular weight of 4200 and p 10.

Результат испытаний приведен в таблице. The test result is shown in the table.

Пример 5. Испытания проводят по методике примера 1, но берут 0,01 г АОТА в 1 мл водного раствора. Example 5. The tests are carried out according to the method of example 1, but take 0.01 g of AOTA in 1 ml of an aqueous solution.

Результат испытаний приведен в таблице. The test result is shown in the table.

Пример 6. Испытания проводят по методике примера 4, но берут АОТА в количестве 0,1 г в 1 мл водного раствора. Example 6. The tests are carried out according to the method of example 4, but take AOTA in the amount of 0.1 g in 1 ml of an aqueous solution.

Результат испытаний приведен в таблице. The test result is shown in the table.

Таким образом, предлагаемый способ позволяет не только увеличить латентный период коразоловых судорог, но в ряде случаев даже их предотвратить. Thus, the proposed method allows not only to increase the latent period of corazole seizures, but in some cases even to prevent them.

Claims (1)

Способ транспорта нейротропных препаратов в мозг путем получения раствора препарата в транспортном средстве с последующим введением этого раствора в кровоток, отличающийся тем, что в качестве транспортного средства используют конъюгат циклодекстринов и полиэтиленоксида формулы
Figure 00000002

где n 6 12;
m 6 7,
причем концентрация нейротропного препарата в водном растворе транспортного средства 0,01 0,1 г/мл.
A method of transporting neurotropic drugs to the brain by obtaining a solution of the drug in a vehicle with the subsequent introduction of this solution into the bloodstream, characterized in that a cyclodextrin and polyethylene oxide conjugate of the formula is used as a vehicle
Figure 00000002

where n 6 12;
m 6 7,
moreover, the concentration of the neurotropic drug in an aqueous solution of the vehicle is 0.01 to 0.1 g / ml
RU93043262A 1993-08-30 1993-08-30 Method of transport of neurotropic preparation to brain RU2094059C1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
RU93043262A RU2094059C1 (en) 1993-08-30 1993-08-30 Method of transport of neurotropic preparation to brain

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU93043262A RU2094059C1 (en) 1993-08-30 1993-08-30 Method of transport of neurotropic preparation to brain

Publications (2)

Publication Number Publication Date
RU93043262A RU93043262A (en) 1996-07-27
RU2094059C1 true RU2094059C1 (en) 1997-10-27

Family

ID=20147064

Family Applications (1)

Application Number Title Priority Date Filing Date
RU93043262A RU2094059C1 (en) 1993-08-30 1993-08-30 Method of transport of neurotropic preparation to brain

Country Status (1)

Country Link
RU (1) RU2094059C1 (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1743907A1 (en) * 2005-07-12 2007-01-17 Gwangju Institute of Science and Technology Conjugate of cyclodextrin and poly(oxyethylene), and process for preparation thereof
US8110179B2 (en) 2002-09-06 2012-02-07 Cerulean Pharma Inc. Cyclodextrin-based polymers for therapeutics delivery
US8497365B2 (en) 2007-01-24 2013-07-30 Mark E. Davis Cyclodextrin-based polymers for therapeutics delivery
US11464871B2 (en) 2012-10-02 2022-10-11 Novartis Ag Methods and systems for polymer precipitation and generation of particles

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Zaise P., Kasparov S. Tawrine Functional neyrochemystry, physiology, cardiology, p. 237, 1990. *

Cited By (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8580243B2 (en) 2002-09-06 2013-11-12 Cerulean Pharma Inc. Cyclodextrin-based polymers for therapeutics delivery
US8603454B2 (en) 2002-09-06 2013-12-10 Cerulean Pharma Inc. Cyclodextrin-based polymers for therapeutics delivery
US8518388B2 (en) 2002-09-06 2013-08-27 Cerulean Pharma Inc. Cyclodextrin-based polymers for therapeutics delivery
US8314230B2 (en) 2002-09-06 2012-11-20 Cerulean Pharma Inc. Cyclodextrin-based polymers for therapeutics delivery
US8389499B2 (en) 2002-09-06 2013-03-05 Cerulean Pharma Inc. Cyclodextrin-based polymers for therapeutics delivery
US8399431B2 (en) 2002-09-06 2013-03-19 Cerulean Pharma Inc. Cyclodextrin-based polymers for therapeutics delivery
US8404662B2 (en) 2002-09-06 2013-03-26 Cerulean Pharma Inc. Cyclodextrin-based polymers for therapeutics delivery
US8475781B2 (en) 2002-09-06 2013-07-02 Cerulean Pharma Inc. Cyclodextrin-based polymers for therapeutics delivery
US8252276B2 (en) 2002-09-06 2012-08-28 Cerulean Pharma Inc. Cyclodextrin-based polymers for therapeutics delivery
US9550860B2 (en) 2002-09-06 2017-01-24 Cerulean Pharma Inc. Cyclodextrin-based polymers for therapeutics delivery
US8580244B2 (en) 2002-09-06 2013-11-12 Cerulean Pharma Inc. Cyclodextrin-based polymers for therapeutics delivery
US8580242B2 (en) 2002-09-06 2013-11-12 Cerulean Pharma Inc. Cyclodextrin-based polymers for therapeutics delivery
US8680202B2 (en) 2002-09-06 2014-03-25 Cerulean Pharma Inc. Cyclodextrin-based polymers for therapeutics delivery
US8110179B2 (en) 2002-09-06 2012-02-07 Cerulean Pharma Inc. Cyclodextrin-based polymers for therapeutics delivery
US8609081B2 (en) 2002-09-06 2013-12-17 Cerulean Pharma Inc. Cyclodextrin-based polymers for therapeutics delivery
EP1743907A1 (en) * 2005-07-12 2007-01-17 Gwangju Institute of Science and Technology Conjugate of cyclodextrin and poly(oxyethylene), and process for preparation thereof
US9610360B2 (en) 2007-01-24 2017-04-04 Ceruliean Pharma Inc. Polymer drug conjugates with tether groups for controlled drug delivery
US8497365B2 (en) 2007-01-24 2013-07-30 Mark E. Davis Cyclodextrin-based polymers for therapeutics delivery
US11464871B2 (en) 2012-10-02 2022-10-11 Novartis Ag Methods and systems for polymer precipitation and generation of particles

Similar Documents

Publication Publication Date Title
EP0441468B1 (en) Gas-containing microparticles composed of polyaldehydes as contrast agents
DE602004009314T2 (en) POLYSIALINSÄUREDERIVATE
DE69434725T2 (en) Cell and serum protein anchors and conjugates
DE69534990T2 (en) CONTRAST AGENTS
RU2375384C2 (en) New block copolymer, micellar preparation and anticarcinogenic agent containing micellar preparation as active component
US5141739A (en) Delivery of x-ray contrast agents using receptor mediated endocytosis
JP3270592B2 (en) Block copolymer-anticancer drug complex pharmaceutical preparation
Mishra et al. Influence of different generations of poly (propylene imine) dendrimers on human erythrocytes
CN106110332A (en) Protein polymer drug conjugate
CA2123576A1 (en) Synthetic peptides for detoxification of bacterial endotoxins and treatment of septic shock
JPH01503464A (en) Synthetic peptides and their use for diagnosis and prevention of influenza virus infection
US4057617A (en) Method of labeling proteins with technetium
JPS63146833A (en) Method and drug for removing acquired glycosylated final product
US20220323591A1 (en) Heparin nano drug carrier system loaded with amino anti-tumor drug and preparation method thereof
JPWO2015025815A1 (en) Polyrotaxane and pharmaceutical composition
Contin et al. Advances in drug delivery, gene delivery and therapeutic agents based on dendritic materials
Liu et al. Synthesis, biodistribution, and imaging of PEGylated-acetylated polyamidoamine dendrimers
RU2094059C1 (en) Method of transport of neurotropic preparation to brain
KR101334780B1 (en) Iodine-containing radial-shape macromolecular compounds, preparation method thereof and contrast medium compositions for CT comprising the same
JPH06206830A (en) Block copolymer-medicinal agent composite and block copolymer
WO2017188257A1 (en) Methylated polyrotaxane and synthesis method for same
WO2010062570A2 (en) COMPOSITIONS COMPRISING CAPTURE PEPTIDES FOR A β-AMYLOID PEPTIDE
CN113413389A (en) Preparation of histone deacetylase inhibitor and preparation method and application thereof
CN1246059A (en) Polymers
CN112672734A (en) Compositions comprising protein and polyalkoxy fatty acyl surfactant